AbCellera Biologics Inc. (ABCL): Price and Financial Metrics

AbCellera Biologics Inc. (ABCL): $7.26

-0.41 (-5.35%)

POWR Rating

Component Grades













Add ABCL to Watchlist
Sign Up

Industry: Biotech



in industry


  • ABCL scores best on the Value dimension, with a Value rank ahead of 86.98% of US stocks.
  • ABCL's strongest trending metric is Value; it's been moving up over the last 179 days.
  • ABCL's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

ABCL Stock Summary

  • AbCellera Biologics Inc's stock had its IPO on December 11, 2020, making it an older stock than merely 1.54% of US equities in our set.
  • Of note is the ratio of AbCellera Biologics Inc's sales and general administrative expense to its total operating expenses; merely 12.92% of US stocks have a lower such ratio.
  • With a year-over-year growth in debt of 496.64%, AbCellera Biologics Inc's debt growth rate surpasses 97.19% of about US stocks.
  • Stocks that are quantitatively similar to ABCL, based on their financial statements, market capitalization, and price volatility, are ACCD, ROKU, QTWO, AEHR, and YELP.
  • To check out AbCellera Biologics Inc's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001703057.

ABCL Valuation Summary

  • In comparison to the median Healthcare stock, ABCL's price/earnings ratio is 7.67% higher, now standing at 39.3.
  • Over the past 38 weeks, ABCL's EV/EBIT ratio has gone up 7805.4.
  • ABCL's EV/EBIT ratio has moved up 7805.4 over the prior 38 weeks.

Below are key valuation metrics over time for ABCL.

Stock Date P/S P/B P/E EV/EBIT
ABCL 2021-08-31 20.1 4.8 39.3 23.8
ABCL 2021-08-30 20.7 5.0 40.7 24.8
ABCL 2021-08-27 21.0 5.1 41.2 25.2
ABCL 2021-08-26 20.8 5.0 40.7 24.8
ABCL 2021-08-25 21.1 5.1 41.4 25.3
ABCL 2021-08-24 20.4 4.9 40.0 24.3

ABCL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ABCL has a Quality Grade of C, ranking ahead of 74.92% of graded US stocks.
  • ABCL's asset turnover comes in at 0.453 -- ranking 98th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows ABCL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2020-12-31 0.453 1 1.811

ABCL Price Target

For more insight on analysts targets of ABCL, see our ABCL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $45.40 Average Broker Recommendation 1.3 (Strong Buy)

ABCL Stock Price Chart Interactive Chart >

Price chart for ABCL

ABCL Price/Volume Stats

Current price $7.26 52-week high $33.64
Prev. close $7.67 52-week low $5.42
Day low $7.05 Volume 1,454,060
Day high $7.60 Avg. volume 1,976,220
50-day MA $8.45 Dividend yield N/A
200-day MA $12.68 Market Cap 2.07B

AbCellera Biologics Inc. (ABCL) Company Bio

AbCellera focuses on therapeutic antibodies, screening, choosing, and analyzing millions of naturally produced antibodies to be used as next-generation drug candidates. It specializes in the fields of biotechnology, medicine, and therapeutics. It was founded in 2012 and headquartered in Vancouver, British Columbia.

ABCL Latest News Stream

Event/Time News Detail
Loading, please wait...

ABCL Latest Social Stream

Loading social stream, please wait...

View Full ABCL Social Stream

Latest ABCL News From Around the Web

Below are the latest news stories about AbCellera Biologics Inc that investors may wish to consider to help them evaluate ABCL as an investment opportunity.

AbCellera Biologics Inc. 2021 Q4 - Results - Earnings Call Presentation

The following slide deck was published by AbCellera Biologics Inc. in conjunction with their 2021 Q4 earnings call....

SA Transcripts on Seeking Alpha | February 24, 2022

AbCellera Biologics GAAP EPS of $0.19 beats by $0.01, revenue of $139.3M beats by $17.44M

AbCellera Biologics press release (ABCL): Q4 GAAP EPS of $0.19 beats by $0.01.Revenue of $139.3M beats by $17.44M.“In 2021 we made significant advancements in executing our…

Seeking Alpha | February 24, 2022

AbCellera Reports Full Year 2021 Business Results

VANCOUVER, British Columbia, February 24, 2022--AbCellera Reports Full Year 2021 Business Results

Yahoo | February 24, 2022

AbCellera Biologics Q4 2021 Earnings Preview

AbCellera Biologics (NASDAQ:ABCL) is scheduled to announce Q4 earnings results on Thursday, February 24th, after market close.The consensus EPS Estimate is $0.17 and the consensus…

Seeking Alpha | February 23, 2022

AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools

VANCOUVER, British Columbia, February 23, 2022--AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools

Yahoo | February 23, 2022

Read More 'ABCL' Stories Here

ABCL Price Returns

1-mo -9.02%
3-mo -12.11%
6-mo N/A
1-year -77.74%
3-year N/A
5-year N/A
YTD -49.23%
2021 -64.46%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4399 seconds.